Literature DB >> 11895295

Siderophore-antibiotic conjugates used as trojan horses against Pseudomonas aeruginosa.

H Budzikiewicz1.   

Abstract

Pseudomonas aeruginosa is a dangerous opportunistic bacterium responsible for frequently lethal hospital (nosocomial) infections. It endangers especially severely injured patients suffering from large wounds or severe burns, as well as persons whose immune system is weakened. An extremely critical situation exists for patients suffering from mucoviscidosis (cystic fibrosis), when P. aeruginosa infects the bronchial tubes. P. aeruginosa is resistant against many disinfecting agents and, more important, an increasing number of strains especially from hospital isolates have become highly resistant against most antibiotics. The low permeability of the outer membrane and an active export mechanism for low molecular weight substances are the main reasons for the resistance. In addition, beta-lactamase activity affects treatment with beta-lactam antibiotics. An approach to overcome the problem of resistance lies in the synthesis of antibiotics conjugated with compounds active as siderophores. In this way the transport ways for iron complexes into the cell can be used ("Trojan Horse strategy"), and the presence of large substituents reduces the export and the beta-lactamase activity. The results obtained with natural (pyoverdins) and synthetic (mainly catecholate) siderophores will be reviewed.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11895295     DOI: 10.2174/1568026013395524

Source DB:  PubMed          Journal:  Curr Top Med Chem        ISSN: 1568-0266            Impact factor:   3.295


  18 in total

Review 1.  Applying insights from biofilm biology to drug development - can a new approach be developed?

Authors:  Thomas Bjarnsholt; Oana Ciofu; Søren Molin; Michael Givskov; Niels Høiby
Journal:  Nat Rev Drug Discov       Date:  2013-10       Impact factor: 84.694

Review 2.  Siderophore-based iron acquisition and pathogen control.

Authors:  Marcus Miethke; Mohamed A Marahiel
Journal:  Microbiol Mol Biol Rev       Date:  2007-09       Impact factor: 11.056

Review 3.  Alkaliphilic bacteria: applications in industrial biotechnology.

Authors:  Indira P Sarethy; Yashi Saxena; Aditi Kapoor; Manisha Sharma; Sanjeev K Sharma; Vandana Gupta; Sanjay Gupta
Journal:  J Ind Microbiol Biotechnol       Date:  2011-04-11       Impact factor: 3.346

4.  Design and synthesis of a novel protected mixed ligand siderophore.

Authors:  Pingyu Ding; Clara E Schous; Marvin J Miller
Journal:  Tetrahedron Lett       Date:  2008-03-31       Impact factor: 2.415

5.  FoxB of Pseudomonas aeruginosa functions in the utilization of the xenosiderophores ferrichrome, ferrioxamine B, and schizokinen: evidence for transport redundancy at the inner membrane.

Authors:  Páraic O Cuív; Damien Keogh; Paul Clarke; Michael O'Connell
Journal:  J Bacteriol       Date:  2006-10-20       Impact factor: 3.490

6.  Production of metabolites as bacterial responses to the marine environment.

Authors:  Carla C C R de Carvalho; Pedro Fernandes
Journal:  Mar Drugs       Date:  2010-03-17       Impact factor: 5.118

7.  FvtA is the receptor for the siderophore vanchrobactin in Vibrio anguillarum: utility as a route of entry for vanchrobactin analogues.

Authors:  Miguel Balado; Carlos R Osorio; Manuel L Lemos
Journal:  Appl Environ Microbiol       Date:  2009-03-06       Impact factor: 4.792

8.  Biosynthetic tailoring of microcin E492m: post-translational modification affords an antibacterial siderophore-peptide conjugate.

Authors:  Elizabeth M Nolan; Michael A Fischbach; Alexander Koglin; Christopher T Walsh
Journal:  J Am Chem Soc       Date:  2007-10-31       Impact factor: 15.419

Review 9.  Is drug release necessary for antimicrobial activity of siderophore-drug conjugates? Syntheses and biological studies of the naturally occurring salmycin "Trojan Horse" antibiotics and synthetic desferridanoxamine-antibiotic conjugates.

Authors:  Timothy A Wencewicz; Ute Möllmann; Timothy E Long; Marvin J Miller
Journal:  Biometals       Date:  2009-02-17       Impact factor: 2.949

10.  The potential of desferrioxamine-gallium as an anti-Pseudomonas therapeutic agent.

Authors:  Ehud Banin; Alina Lozinski; Keith M Brady; Eduard Berenshtein; Phillip W Butterfield; Maya Moshe; Mordechai Chevion; Everett Peter Greenberg; Eyal Banin
Journal:  Proc Natl Acad Sci U S A       Date:  2008-10-17       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.